FOLFIRI方案一线治疗进展期胃癌的临床观察

目的探讨伊立替康（开普拓,IRI,CPT-11）联合氟尿嘧啶（5-Fu）、甲酰四氢叶酸（CF）一线治疗进展期胃癌的疗效及毒性作用。方法对2006年6月至2008年12月采用该方案治疗的进展期胃癌36例患者进行回顾性分析,每例患者至少接受6个周期化疗。用法：CPT-11180mg/m^2,静脉滴注30～90min,第1天;CF400mg/m^2,静脉滴注2h,第1天;5-Fu400mg/m^2,继CF后静脉推注,然后2400mg/m^2,持续静脉滴注,46h,第1天,14d为1个周期。每3～4个周期后按照RECIST实体瘤近期客观疗效评定标准进行疗效评价。结果CR2例,占5.6%;PR14例,占38.9%;SD9例,占25.0%;PD11例,占30.6%;客观有效率（CR＋PR）为44.4%;临床获益率（PR＋CR＋SD）为69.4%,中位疾病进展时间（TTP）5.9个月;中位生存期（MST）10.1个月。不良反应主要为骨髓抑制、延迟性腹泻。结论FOLFIRI方案一线治疗进展期胃癌,疗效较好,毒副反应可耐受,值得临床进一步应用与推广。

FOLFIRI regimen in first-line treatment for advanced gastric cancer:a study of 36 patients

Objective To observe the efficacy and safety of FOLFIRI regimen in first-line treatment fo patients with advanced gastric cancer.Methods Thirty-six patients with advanced gastric cancer treated with FOLFIRI regimen form June 2006 to Dec were reviewed and analyzed.All patients received at least 6 cycles of chemotherapy.The regimen included irinotecon(CPT-11) 180 mg/m2 d1,iv dripping in 30-90 minutes;leucovorin(CF) 400 mg/m2 iv infusion over 2 hours on day 1;fluorouracil 400 mg/m2 iv bolus on day 1,then 2400 ...